Evofem Biosciences Price Performance
Shares of EVFM opened at $0.08 on Thursday. Evofem Biosciences has a one year low of $0.07 and a one year high of $8.10. The company has a 50-day moving average of $0.13 and a two-hundred day moving average of $0.46. The stock has a market cap of $9.63 million, a price-to-earnings ratio of 0.00 and a beta of -1.21.
Wall Street Analysts Forecast Growth
Several research analysts have commented on EVFM shares. HC Wainwright raised their target price on shares of Evofem Biosciences to $4.00 and gave the stock a “buy” rating in a report on Monday, August 15th. Stifel Nicolaus cut shares of Evofem Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 12th.
Institutional Trading of Evofem Biosciences
Evofem Biosciences Company Profile
Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.
- Get a free copy of the StockNews.com research report on Evofem Biosciences (EVFM)
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.